Literature DB >> 25388590

Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.

P Mota1, H C Silva, M J Soares, A Pego, M Loureiro, C Robalo Cordeiro, F J Regateiro.   

Abstract

OBJECTIVES: Tobacco exposure remains the main etiologic factor for lung cancer (LC). Interactions between environment and individual genetic profile are particularly important for this disease. The aim of this study was to evaluate the contribution of CYP1A1*2A, CYP1A1*2C, CYP2D6*4, GSTP1, GSTM1, GSTT1 and NAT2 polymorphisms for the susceptibility to LC in a Portuguese population considering their demographic and clinical characteristics.
MATERIALS AND METHODS: A total of 200 LC and 247 controls subjects from the Centre of Portugal were studied. Clinical and demographic characteristics were collected from clinical files and by individual questionnaires. Polymorphisms of CYP1A1*2A, CYP1A1*2C, CYP2D6*4, GSTP1, GSTM1, GSTT1 and NAT2 were genotyped using PCR-RFLP, PCR multiplex, ARMS and real time.
RESULTS: Gender, family history of cancer, smoke cessation and alcohol consumption were independent risk factors (p < 0.05). Associations found between phases I and II genes and LC population reveal a sex dependent distribution. Logistic regression analysis demonstrates that enhanced activation by CYPs, associated by reduced or loss of function of phase II enzymes, can lead to a greater risk. GSTP1 and NAT2 polymorphisms studied have a significant contribution for the histological tumour types and the presence of metastases, at time of diagnosis, respectively, when males with smoking habits were considered.
CONCLUSION: Multiple interactions between environment and individual characteristics are clearly associated to this disease. Variants of the detoxification genes may act synergistically contributing to this disease and modifying the risk posed by smoking and sex. The GSTT1*0 and GSTP1 (Ile462Val) might contribute to the malignant phenotype through different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25388590     DOI: 10.1007/s00432-014-1868-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  39 in total

1.  A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid.

Authors:  C A Smith; M Wadelius; A C Gough; D J Harrison; C R Wolf; A Rane
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

2.  Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.

Authors:  K Nakachi; K Imai; S Hayashi; J Watanabe; K Kawajiri
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 3.  Modulation of xenobiotic metabolising enzymes by anticarcinogens -- focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis.

Authors:  Beatrice Pool-Zobel; Selvaraju Veeriah; Frank-D Böhmer
Journal:  Mutat Res       Date:  2005-08-03       Impact factor: 2.433

4.  Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer.

Authors:  C M Wright; J E Larsen; M L Colosimo; J J Barr; L Chen; R E McLachlan; I A Yang; R V Bowman; K M Fong
Journal:  Eur Respir J       Date:  2009-07-16       Impact factor: 16.671

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

Review 6.  Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis.

Authors:  C Carlsten; G S Sagoo; A J Frodsham; W Burke; J P T Higgins
Journal:  Am J Epidemiol       Date:  2008-02-12       Impact factor: 4.897

7.  Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.

Authors:  A Rostami-Hodjegan; M S Lennard; H F Woods; G T Tucker
Journal:  Pharmacogenetics       Date:  1998-06

Review 8.  Lung cancer in Europe in 2000: epidemiology, prevention, and early detection.

Authors:  Jerzy E Tyczynski; Freddie Bray; D Maxwell Parkin
Journal:  Lancet Oncol       Date:  2003-01       Impact factor: 41.316

Review 9.  The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism.

Authors:  Sigal Ben-Zaken Cohen; Peter D Paré; S F Paul Man; Don D Sin
Journal:  Am J Respir Crit Care Med       Date:  2007-04-05       Impact factor: 21.405

Review 10.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.

Authors:  A Parsons; A Daley; R Begh; P Aveyard
Journal:  BMJ       Date:  2010-01-21
View more
  8 in total

1.  Adverse Outcomes Associated with Cigarette Smoke Radicals Related to Damage to Protein-disulfide Isomerase.

Authors:  Harshavardhan Kenche; Zhi-Wei Ye; Kokilavani Vedagiri; Dylan M Richards; Xing-Huang Gao; Kenneth D Tew; Danyelle M Townsend; Anna Blumental-Perry
Journal:  J Biol Chem       Date:  2016-01-04       Impact factor: 5.157

Review 2.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Lung cancer susceptibility from GSTM1 deletion and air pollution with smoking status: a meta-prediction of worldwide populations.

Authors:  Pojui Yu; Joyce D Kusuma; Maria Aurora R Suarez; Shyang-Yun Pamela Koong Shiao
Journal:  Oncotarget       Date:  2018-07-24

4.  The Relation between Polymorphisms in Exon 5 and Exon 6 of GSTP1 Gene and the Risk of Lung Cancer in Iranian People

Authors:  Gholamreza Shahsavari; Ali Amiri; Masoud Shamaei; Glavizh Adibhesami; Amirnader Emami Razavi; Mehdi Birjandi; Mihan Pourabdollah
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

5.  Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors: Results from case-control studies in France and New Caledonia.

Authors:  Catherine Tcheandjieu; Emilie Cordina-Duverger; Claire Mulot; Dominique Baron-Dubourdieu; Anne-Valérie Guizard; Claire Schvartz; Pierre Laurent-Puig; Pascal Guénel; Thérèse Truong
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  Genetic Polymorphisms of Xenobiotic Metabolizing Genes (GSTM1, GSTT1, GSTP1), Gene-Gene Interaction with Association to Lung Cancer Risk in North India; A Case Control Study.

Authors:  Sonia Tiwari; Sivakumar Vijayaraghavalu; Munish Kumar
Journal:  Asian Pac J Cancer Prev       Date:  2019-09-01

7.  Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.

Authors:  Roxana Moslehi; Elizabeth Freedman; Nur Zeinomar; Carmela Veneroso; Paul H Levine
Journal:  BMC Cancer       Date:  2016-05-26       Impact factor: 4.430

8.  Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) Polymorphisms and Lung Cancer Risk among a Select Group of Iranian People

Authors:  Glavizh Adibhesami; Gholam Reza Shahsavari; Ali Amiri; Amir Nader Emami Razavi; Masoud Shamaei; Mehdi Birjandi
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.